pyrazines has been researched along with Abnormality, Heart in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lafuente-Romero, A; Rodriguez Ogando, A | 1 |
| Alejos, J; Drogalis-Kim, DE; Gallotti, R; Satou, G | 1 |
| Beghetti, M; Channick, RN; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Aggarwal, S; Fagoaga, OR; L'Ecuyer, TJ; Zinn, MD | 1 |
| Chen, DZ; Huang, RJ; Liao, CX | 1 |
2 trial(s) available for pyrazines and Abnormality, Heart
| Article | Year |
|---|---|
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Topics: Acetamides; Adult; Antihypertensive Agents; Cardiac Surgical Procedures; Disease Progression; Double-Blind Method; Drug Monitoring; Early Medical Intervention; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Proportional Hazards Models; Pyrazines; Treatment Outcome | 2019 |
[Effect of tetramethylpyrazine on endothelin, von Willebrand factor and thromboxane A2 during cardiopulmonary bypass in patients of congenital heart disease with pulmonary hypertension].
Topics: Adolescent; Adult; Calcium Channel Blockers; Cardiopulmonary Bypass; Child; Child, Preschool; Endothelins; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pyrazines; Thromboxane B2; von Willebrand Factor | 2003 |
3 other study(ies) available for pyrazines and Abnormality, Heart
| Article | Year |
|---|---|
Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients.
Topics: Acetamides; Adult; Antihypertensive Agents; Child; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Pyrazines | 2021 |
Single-Center Experience Using Selexipag in a Pediatric Population.
Topics: Acetamides; Adolescent; Antihypertensive Agents; Child; Epoprostenol; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pyrazines; Treatment Outcome; Walk Test; Young Adult | 2017 |
Bortezomib use in a pediatric cardiac transplant center.
Topics: Adolescent; Adult; Antibodies; Biopsy; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Graft Rejection; Heart Defects, Congenital; Heart Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Isoantibodies; Male; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |